Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
FOXO Technologies ( (FOXO) ) has shared an update.
On July 18, 2025, FOXO Technologies Inc. announced its Board of Directors’ decision to pursue the spin-off of its subsidiary, FOXO Labs, Inc., which focuses on epigenetics. This move aims to enhance the company’s business strategy by creating a subscription-based revenue model for personal health and longevity, potentially increasing value for shareholders and simplifying business models for both FOXO Technologies and the newly independent FOXO Labs.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the biotechnology industry, focusing on improving human health and lifespan through advanced technology and product solutions. The company owns and operates subsidiaries including FOXO Labs, Inc., which specializes in epigenetic biomarker development, and other healthcare facilities in East Tennessee.
Average Trading Volume: 7,314,504
Technical Sentiment Signal: Sell
Current Market Cap: $2.71M
See more data about FOXO stock on TipRanks’ Stock Analysis page.